ANVS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
17.0M
+18.0%
14.4M
-20.2%
18.0M
+85.6%
9.7M
+30.5%
7.4M
R&D
15.8M
+31.4%
12.0M
-28.2%
16.7M
+91.1%
8.8M
+39.1%
6.3M
SG&A
1.2M
-49.8%
2.4M
+83.5%
1.3M
+35.2%
955.2K
-16.5%
1.1M
Operating Income
-16969108
-18.0%
-14377712
+20.2%
-18012182
-85.6%
-9706149
-30.5%
-7434975
EBITDA
-16969108
-18.0%
-14377712
+20.2%
-18012182
-85.6%
-9706149
-30.5%
-7434975
Net Income
-9462136
+36.2%
-14820815
+15.8%
-17606382
-79.0%
-9834412
-35.4%
-7262658
EPS (Basic)
$-0.22
+45.0%
$-0.40
+36.5%
$-0.63
-65.8%
$-0.38
-2.7%
$-0.37
EPS (Diluted)
$-0.22
+45.0%
$-0.40
+36.5%
$-0.63
-65.8%
$-0.38
-2.7%
$-0.37
Shares (Diluted)
42.6M
+13.6%
37.5M
+34.7%
27.8M
+8.8%
25.6M
+30.1%
19.7M
Annovis Bio (ANVS) — Financials